Share on StockTwits
 

DexCom (NASDAQ:DXCM)’s share price reached a new 52-week high during mid-day trading on Thursday, Analyst Ratings Network reports. The stock traded as high as $39.23 and last traded at $38.99, with a volume of 658,216 shares traded. The stock had previously closed at $37.56.

DXCM has been the subject of a number of recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of DexCom in a research note to investors on Friday, January 24th. They now have a $44.00 price target on the stock. Separately, analysts at Benchmark Co. raised their price target on shares of DexCom from $40.00 to $44.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $34.00 price target on the stock. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.10.

In other DexCom news, EVP Steven Robert Pacelli unloaded 14,000 shares of the stock on the open market in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $36.49, for a total transaction of $510,860.00. Following the sale, the executive vice president now directly owns 195,865 shares in the company, valued at approximately $7,147,114. The transaction was disclosed in a filing with the SEC, which is available at this link.

DexCom has a 1-year low of $14.05 and a 1-year high of $38.20. The stock’s 50-day moving average is $35.64 and its 200-day moving average is $29.97. The company’s market cap is $2.817 billion.

DexCom (NASDAQ:DXCM) last released its earnings data on Wednesday, November 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.04. The company had revenue of $42.90 million for the quarter, compared to the consensus estimate of $35.90 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. The company’s revenue for the quarter was up 85.7% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.46 earnings per share for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.